Optomed Plc: Disclosure under Chapter 9, Section 5 of the Securities Markets Act regarding change in holdings

OPTOMED PLC          STOCK EXCHANGE RELEASE                      9 December 2019 at 7 p.m.

Optomed Plc: Disclosure under Chapter 9, Section 5 of the Securities Markets Act regarding change in holdings

Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Halma plc. According to the notification, the total holdings in Optomed shares and votes indirectly held by Halma plc (directly held by Halma Ventures Limited) decreased to 0 percent of all of the registered shares in Optomed on 5 December 2019. The change in the position was due to a share lending agreement entered into between Halma Ventures Limited and Carnegie Investment Bank AB (publ) (“Carnegie”) on 5 December 2019, according to which Carnegie has borrowed 922,052 shares in the Company on 5 December 2019. Upon falling due of the share lending agreement, Carnegie is under an obligation to return the shares to the extent Carnegie would not use the over-allotment option granted to it by Halma Ventures Limited in connection with the initial public offering.

The total number of the Company’s registered shares amounts to 14,003,144 shares. Each share entitles to one (1) vote.

The total position of Halma plc subject to the notification:

  % of shares and voting rights (total of A) % of shares and voting rights through financial instruments (total of B) Total of both in % (A+B)
Resulting situation on the date on which threshold was crossed or reached 0.0 - 0.0
Position of previous notification (if applicable) - - -

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights

Class/type of shares ISIN code Number of shares and voting rights % of shares and voting rights
Direct
(SMA 9:5)
Indirect
(SMA 9:6 ja 9:7)
Direct
(SMA 9:5)
Indirect 
(SMA 9:6 ja 9:7)
FI4000410881 - 0.0 - 0.0
SUBTOTAL A 0 0.0

Information in relation to the person subject to the notification obligation as contained in the notification

The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both
Halma plc - - -
Halma Ventures Limited 0.0 - 0.0

Further enquiries

Lars Lindqvist, CFO, Optomed Plc, lars.lindqvist@optomed.com

Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com, tel. +358 50 562 4077

Distribution

Nasdaq Helsinki Ltd

Principal media

www.optomed.com

Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 52 international patents protecting the technology. In 2018, Optomed’s revenue reached EUR 12.7 million and pro forma revenue with the acquisition of Commit; Oy amounted to EUR 14.5 million. At the end of September 2019, Optomed employed 105 professionals.

Subscribe